Internal Medicine, Rheumatology · Myrtle Beach, SC
NPI
1760823553
Since 2013
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
945 82nd Pkwy
Myrtle Beach, SC, 29572
Phone (843) 497-5929
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.5M
268,118 services
Medicare patients, 2024
789
Average age 73
Drug cost, 2024
$2.0M
2,573 prescriptions
Company payments, 2025
$3,522
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rabih Nayfe was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 106,000 times for 68 patients. In total Rabih Nayfe billed 268,118 services in 94 codes, and Medicare paid $2.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-08-06.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 106,000 | 68 | $3.61 | $383K |
| J3262 Injection, tocilizumab, 1 mg | Office | 75,320 | 37 | $4.71 | $355K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 39,449 | 90 | $9.11 | $359K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 23,100 | 110 | $33.90 | $783K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 6,300 | 12 | $8.16 | $51K |
| J0897 Injection, denosumab, 1 mg | Office | 1,560 | 25 | $20.00 | $31K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 690 | 82 | $0.74 | $514 |
| 99214 Office E&M - Established | Office | 627 | 382 | $86.82 | $54K |
| 96401 Chemotherapy Administration | Office | 561 | 81 | $49.92 | $28K |
| 96413 Chemotherapy Administration | Office | 537 | 229 | $89.16 | $48K |
| 36415 Venipuncture Blood Collection | Office | 495 | 286 | $8.65 | $4,282 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 448 | 312 | $11.99 | $5,374 |
| 85652 Clinical Chemistry | Office | 445 | 248 | $2.64 | $1,177 |
| 85025 Blood Count | Office | 386 | 214 | $7.61 | $2,937 |
| 80076 Clinical Chemistry | Office | 214 | 103 | $7.97 | $1,706 |
By year: 2022 $2.5M for 203,337 services; 2023 $2.3M for 226,564 services; 2024 $2.5M for 268,118 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 495 | 286 | $8.65 | $4,282 |
| 85652 Clinical Chemistry | 445 | 248 | $2.64 | $1,177 |
| 85025 Blood Count | 386 | 214 | $7.61 | $2,937 |
| 80076 Clinical Chemistry | 214 | 103 | $7.97 | $1,706 |
| 82565 Clinical Chemistry | 184 | 90 | $5.02 | $924 |
| 86140 Clinical Chemistry | 141 | 105 | $5.08 | $716 |
| 80053 Clinical Chemistry | 137 | 108 | $10.27 | $1,408 |
| 82306 Clinical Chemistry | 55 | 54 | $29.01 | $1,596 |
| 84550 Clinical Chemistry | 41 | 32 | $4.43 | $182 |
| 80048 Clinical Chemistry | 32 | 31 | $8.29 | $265 |
Medicare prescription drug claims, 2024
In 2024, the drug Rabih Nayfe prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 401 prescriptions and refills. In total Rabih Nayfe wrote 2,573 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 401 | 1,062 | 123 | $14K |
| Prednisone Generic | 382 | 665 | 151 | $2,603 |
| Hydroxychloroquine Sulfate Generic | 308 | 897 | 100 | $21K |
| Leflunomide Generic | 133 | 384 | 44 | $8,919 |
| Allopurinol Generic | 131 | 387 | 40 | $1,329 |
| Folic Acid Generic | 107 | 313 | 31 | $1,117 |
| Tramadol Hcl Generic | 71 | 79 | 26 | $443 |
| Rinvoq Upadacitinib | 70 | 78 | Under 11 | $499K |
| Gabapentin Generic | 68 | 173 | 20 | $1,162 |
| Alendronate Sodium Generic | 67 | 162 | 20 | $605 |
| Celecoxib Generic | 60 | 125 | 29 | $3,120 |
| Mycophenolate Mofetil Generic | 39 | 85 | 13 | $4,654 |
| Xeljanz Xr Tofacitinib Citrate | 38 | 52 | Under 11 | $316K |
| Sulfasalazine Generic | 35 | 104 | Under 11 | $1,612 |
| Meloxicam Generic | 33 | 61 | 12 | $86.11 |
Brand drugs: - claims; generic drugs: 2,136 claims; opioid claims: 111.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rabih Nayfe $3,522 ($3,522 in general payments such as food, travel and fees) from 16 companies. The largest payer was Abbvie Inc. with $1,189.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 42 | $1,189 |
| Amgen Inc. AMGN | 46 | $738 |
| UCB, Inc. UCB.BR | 22 | $454 |
| Janssen Biotech, Inc. JNJ | 19 | $308 |
| Novartis Pharmaceuticals Corporation NVS | 19 | $234 |
| Radius Health, Inc. | 10 | $169 |
| E.R. Squibb & Sons, L.L.C. BMY | 7 | $115 |
| Novo Nordisk Inc NVO | 2 | $61.86 |
| Madrigal Pharmaceuticals MDGL | 1 | $44.28 |
| Pfizer Inc. PFE | 3 | $42.09 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.